Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Allergy Therapeutics Shares (LSE:AGY) Fell 12.5% in the Early-November 2026 Session

Allergy Therapeutics develops and commercialises allergy immunotherapy products and is quoted on AIM, the London Stock Exchange's junior market. (LSE:AGY) The company has been through a period of substantial corporate activity, including funding updates, an authority for the allotment of new shares and, in …

Ankur Sharma | 04 November 2026

Why MicroSalt Shares (LSE:SALT) Dropped 11.6% in the Early-November 2026 Session

MicroSalt produces a reduced-sodium salt technology marketed as a healthier alternative for food manufacturers and consumers, and is quoted on AIM, the London Stock Exchange's junior market. (LSE:SALT) The company has issued a steady stream of commercial news, including new customer wins, a joint …

Ankur Sharma | 04 November 2026

Why HemoGenyx Pharmaceuticals Plc (LSE: HEMO) Rose Nearly 7% in November 2026

HemoGenyx has been advancing its Phase I trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukaemia (AML). (LSE:HEMO) Company announcements during 2026 reported the treatment of a third patient and continued recruitment, with the group opening its first clinical …

Ankur Sharma | 04 November 2026

Why Provexis (LSE:PXS) Rose 12.5% on AIM in November 2026

Provexis owns and licenses Fruitflow, a water-soluble tomato extract marketed for its heart-health and blood-flow properties. (LSE:PXS) The company's recent history has been unusually busy: it reported a delay in publishing its annual accounts, which led to a temporary suspension of its shares, followed …

Ankur Sharma | 04 November 2026

Why Eden Biosolutions (LSE:EDEN) Climbed 22% on AIM in November 2026

Eden's regulatory newsflow through 2026 has centred on funding and commercial progress, including the satisfaction of conditions and completion of a conditional placing with a total-voting-rights update, and a trading update. (LSE:EDEN) On the available evidence, the change appears consistent with heightened trading interest …

Ankur Sharma | 04 November 2026

Avacta (LSE:AVCT) Back in the AIM Biotech Spotlight as Cancer Drug Conjugates and Funding Take Centre Stage

Biotech shares often move on single data points or funding announcements, and sentiment is affected by the cost of capital. With the 10-year giltYieldat about 5.3% and the AIM All-Share down 0.4%, investors are weighing how long smaller drug developers can sustain research spending. …

Ankur Sharma | 04 November 2026

NIOX Group (LSE:NIOX) Breathes Fresh Life Into AIM Watchlists as Asthma Testing Demand and US Reimbursement Take Focus

Healthcare stocks tend to receive attention on days whenMiningand consumer names retreat, and NIOX (LSE:NIOX) fits the profile of a specialised growth company. Its FeNO measurement technology helps clinicians assess airway inflammation, and clinical guidelines in several markets endorse such testing. The United States …

Ankur Sharma | 04 November 2026

Scancell (LSE:SCLP) Moves Into the AIM Biotech Spotlight as Cancer Immunotherapy Data and Funding Stay Centre Stage

Clinical-stage healthcare companies typically move on data, regulatory feedback and funding developments rather than on the macro backdrop, but sentiment still matters. The AIM All-Share slipped 0.4% on Tuesday and the FTSE 100 fell 1.1%, with US midterm elections and the Bank of England …

Ankur Sharma | 04 November 2026

Tristel (LSE:TSTL) Steps Into the AIM Spotlight as Infection Prevention Specialist Eyes US Expansion

Healthcare small caps often attract interest when broader markets turn cautious, becauseDemandfor infection control is driven by clinical protocols rather than the economic cycle. Tristel (LSE:TSTL) has also been a talking point for its efforts to broaden its footprint beyond the UK, in particular …

Ankur Sharma | 04 November 2026

FTSE 250 Vet Group CVS Group (LSE:CVSG) Fights Weak UK Footfall With Australian Expansion as Regulatory Spotlight Stays on the Sector

The veterinary sector has been a hot topic for UK households and investors alike. Rising vet bills have attracted public and political attention, and the regulator's investigation into competition in the market has raised questions about pricing transparency, prescription costs and the role of …

Ankur Sharma | 04 November 2026
Support

Hi! How can we help you today?

Loading…